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Abstract 
Background: Campylobacter concisus is a commensal of the human oral flora that has been linked to prolonged diar‑
rhea and inflammatory bowel disease (IBD). It has been detected more often from intestinal biopsies in patients with 
IBD compared to healthy controls using PCR‑based techniques, whereas the number of C. concisus culture‑positive 
biopsies in previous studies has been very limited. Determining the rate of viable isolates present in the gut mucosa 
is of great importance when evaluating the role in different disease presentations. We therefore investigated a novel 
two‑step cultivation procedure combining anaerobic and microaerobic incubation from several gut mucosal sites to 
improve isolate yield, and compared this to PCR results, from IBD patients and healthy controls.
Results: Cultivation with the novel two‑step procedure yielded a higher rate of C. concisus isolates from mucosal 
biopsies than previously reported by other methods. From 52 IBD patients, 52/245 (21 %) biopsies were culture posi‑
tive for C. concisus, while 121/245 (49 %) of biopsies were PCR positive. For 26 healthy controls, the numbers were 
23/182 (13 %) and 66/182 (36 %), respectively (p < 0.001). The rate of cultivation and PCR detection was higher for IBD 
patients compared to healthy controls (p = 0.021, p = 0.008, respectively).
Conclusions: Patients with IBD had a higher prevalence of C. concisus than healthy controls, by both cultivation 
and PCR detection. We found a higher rate of C. concisus isolates from gut mucosal biopsies in both IBD patients and 
healthy controls than in preceding studies, indicating that colonization of C. concisus in the gastrointestinal tract is 
more extensive than previously assumed.
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Background
The genus Campylobacter consists of 26 species, whereof 
Campylobacter jejuni is the leading cause of gastroenteri-
tis in humans worldwide [1]. Meanwhile, mounting evi-
dence has brought attention to the clinical significance of 
other Campylobacter species in gastrointestinal disease, 
therefore termed emerging Campylobacter species [2]. 
Campylobacter jejuni, Campylobacter coli and Campy-
lobacter lari are thermophilic, with poultry as the main 
reservoir and source of infection in humans. In con-
trast, the optimal growth temperature for many emerg-
ing Campylobacter species is 37  °C [3] suggesting that 
mammals, including humans, could serve as ideal reser-
voir candidates.
Several studies have associated Campylobacter con-
cisus to prolonged gastroenteritis, in children as well as 
adults [4–6]. Furthermore, recent studies have found a 
high prevalence of C. concisus DNA in mucosal biopsies 
from patients with inflammatory bowel disease (IBD) 
using PCR-based methods [7–10], whereas cultivation 
of isolates has been sparse and to date, only few isolates 
have been recovered. A recent meta-analysis of these 
previous studies found that C. concisus was associated 
with an increased risk of IBD (OR 3.76, p = 0.006) [11]. 
Enteric C. concisus isolates have been shown to possess 
pathogenic capacities such as cell bound and secreted 
hemolytic activity that can facilitate increased intestinal 
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permeability—a pathognomonic finding in IBD [12]. 
However, a vast difference in pathogenic properties 
between isolates exist and a study examining the genomes 
of different enteric C. concisus isolates has verified the 
pronounced diversity of the species [13]. The two major 
disorders that comprise IBD are Crohn’s disease (CD) and 
ulcerative colitis (UC). While these disorders are thought 
similar in etiology, the pathogenesis is very different, with 
CD affecting the entire gastrointestinal tract and UC 
only the large intestine [14]. The aim of the present study 
was to assess whether cultivation of C. concisus from gut 
mucosal tissue could be optimized by incubating in both 
microaerobic and anaerobic atmospheres to yield a higher 
number of isolates, and to compare these results to a pol-
ymerase chain reaction (PCR) method.
Methods
In this study, we tested the effect of cultivation in differ-
ent atmospheres on recovery of emerging Campylobacter 
species from gut mucosal biopsies, collected from 52 adult 
patients with IBD and 26 healthy controls, and compared 
the cultivation results to detection by PCR. Twenty-seven 
of the IBD patients had previously undergone surgery with 
restorative proctocolectomy and ileal-pouch-anal-anasto-
mosis (IPAA) due to severe UC [15]. All IBD patients had 
a disease history of at least 1 year, and no study partici-
pants had received antibiotics in the month prior to study 
enrolment. Healthy controls and IBD patients except for 
those with IPAA had undergone standard bowel prepa-
rations prior to the procedure. Patients with IPAA were 
flushed with saline at the start of the endoscopy. An over-
view of the study participants is presented in Table 1. The 
study was approved by the Regional Ethics Committee of 
Northern Jutland, Denmark (N-20130070), and all study 
participants provided written consent.
Biopsies were collected from the terminal ileum, 
cecum, ascending-, transverse-, descending-, sigmoid 
colon and rectum. From IPAA patients, biopsies were 
collected from the ileum, and the proximal and distal 
part of the pouch. Saliva samples from each patient were 
also collected, and stool samples from all but four IBD 
patients and one healthy control. Healthy controls were 
patients undergoing colonoscopy for other indications 
such as screening for colorectal cancer, or abdominal 
pain without any symptoms of enteritis. Biopsies were 
collected with sterile forceps (Medwork, Braun Scandi-
navia, Denmark), which were discarded after each indi-
vidual biopsy. Tissue samples were promptly placed in 
sterile containers with 0.5 ml sterile saline and immedi-
ately taken to the laboratory, rendering a transit time of 
less than 30 min at ambient temperature.
Each biopsy was smeared onto two non-selective 5  % 
blood agar plates with added yeast extract (SSI Diagnos-
tica, Denmark) using sterile inoculation loops. Cultivation 
was then carried out as a two-step procedure: Initially, 
one plate was incubated for 48  h in microaerobic (80  % 
N2, 10 % CO2, 5 % H2, 6 % O2) and the other in anaerobic 
(80 % N2, 10 % CO2, 10 % H2) conditions, attained using 
the Anoxomat Mart II system (Mart Microbiology B.V., 
Netherlands). Following 48  h of incubation, inoculation 
loops were used to harvest approximately 100  µg bacte-
rial mass by streaking across each agar plate. The bacterial 
mass was liquefied by addition of 50 µl sterile saline and 
brief vortexing. Using sterile pipettes, the emulsion was 
transferred onto two 5  % blood agar plates with added 
yeast extract (SSI Diagnostica, Denmark) and polycar-
bonate filters (0.6 µm pore size) (Whatman® Nuclepore™, 
Sigma-Aldrich, MO, USA), then incubated for 60  min 
at 37  °C in an ambient atmosphere, using a previously 
described method [16]. Subsequently, all plates were 
incubated in microaerobic conditions for a total of 96 h. 
On daily inspection, colonies resembling Campylobacter 
spp. were subjected to microscopic examination and spe-
cies specificity was confirmed by MALDI-TOF (BRUKER 
DALTONIK GmbH, Bremen, Germany) analysis [17]. 
Campylobacter concisus isolates were also subjected to 
qPCR analysis (Life Technologies, Carlsbad, CA, USA) 
with the C. concisus specific primers targeting the 16S 
rRNA gene with modifications of the methods of Mahen-
dran et al. [9]. Stool and saliva samples were cultivated by 
previously described methods [16], and incubated in a 
microaerobic atmosphere only.
After cultivation, biopsies were prepared for PCR 
examination by initial disruption of tissue samples 
using the Tissuelyser II (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. DNA was 
extracted using an on-board protocol with the NucliS-
ENS® easyMAG® platform (BioMérieux, Marcy-l’Étoile, 
France). Real-time PCR (Life Technologies, Carlsbad, 
CA, USA) was then performed with modifications of the 
methods previously described by Mahendran et  al. [9], 
with initial amplification of bacterial 16S rRNA genes, 
followed by PCR purification and finally C. concisus 
specific PCR using the primers Conc Fmod and Conc 
R2 using the conditions described by Watt et  al. [18]. 
Table 1 Disease subgroups, sex, age and  number of  sam-
ples collected from IBD patients and healthy controls (HC)
IBD HC
Disease CD UC IPAA –
Number 9 16 27 26
Sex, male (%) 4 (44) 7 (44) 13 (50) 15 (58)
Age, median (IQR) 42 (31–49) 59 (40–63) 43 (35–50) 57 (49–66)
Samples, median 
(range)
7 (6–7) 7 (4–7) 3 (3–3) 7 (7–7)
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Amplified PCR products were visualized on QiAXcel 
Advanced screen gel for verification of product size (Qia-
gen, Hilden, Germany).
Data was analysed using Stata 14 (Statacorp LP, Texas, 
USA). Fischer’s exact test was used for dichotomous vari-
ables and McNemar’s test for paired nominal data. A p 
value < 0.05 was considered statistically significant.
Results
In total, 427 biopsies were collected from 78 subjects. 
From gut mucosal biopsies, isolates that grew in both 
microaerobic and anaerobic atmospheres were collected 
separately, rendering a total of 99 isolates. Twenty-nine 
isolates were derived from microaerobic and 22 from 
anaerobic incubation exclusively (p  =  0.40). From 24 
biopsies, isolates grew in both atmospheres (Table 2).
In all IBD patients, a total of 52/245 (21  %) biopsies 
were culture positive for C. concisus, while 121/245 
(49  %) were PCR positive (p  <  0.001) For healthy con-
trols, the numbers were 23/182 (13 %) and 66/182 (36 %), 
respectively (p < 0.001). The rate of cultivation and PCR 
detection was higher for IBD patients compared to 
healthy controls (p = 0.021 and p = 0.008, respectively). 
Interestingly, the rate of C. concisus cultivation and PCR 
detection was significantly higher for IPAA patients com-
pared to other IBD patients (p = 0.0001 and p = 0.0006, 
respectively), and there was no significant difference 
between CD and other UC patients. The number of cul-
ture and PCR positive biopsies from different disease cat-
egories are shown in Table 3.
From stool samples, 12/48 (25 %) of IBD patients were 
culture positive, while 19/48 (40 %) were positive by PCR 
detection. When comparing IPAA patients to other IBD 
patients, there was no difference in isolation from stool 
by cultivation (p = 0.18), but a higher detection rate by 
PCR (p = 0.001). For healthy controls, the numbers were 
3/25 (12  %) and 5/25 (20  %) respectively. As expected, 
C. concisus was abundant in saliva samples from both 
IBD patients and healthy controls, with 34/52 (65 %) IBD 
and 18/26 (70 %) healthy controls being culture positive, 
47/52 (90 %) and 23/26 (88 %) PCR positive, respectively. 
When assessing the number of positive subjects with 
at least one positive C. concisus biopsy, stool or saliva 
sample, there was no difference between groups with 
either cultivation or PCR methods, although there was a 
trend towards higher PCR detection rates from biopsies 
and stool in IBD patients compared to healthy controls 
(Fig. 1). Agar plates were also inspected for Campylobac-
ter species other than C. concisus. The majority of these 
were C. ureolyticus, with six isolates recovered from six 
different IBD patients. One of these patients was also 
positive for C. concisus. One IBD patient had C. curvus 
in three different biopsies; another had one C. showae 
isolate in one biopsy. Both of these patients were also 
positive for C. concisus. In the healthy control group, 
isolates of C. ureolyticus and C. showae were recovered 
from four different individuals, whereof two were also 
positive for C. concisus. No thermophilic Campylobac-
ter species were isolated from IBD patients or healthy 
controls.
Discussion
To our knowledge, this is the first study to address the 
issue of difficulty in cultivating emerging Campylobac-
ter species from mucosal tissue. While PCR methods are 
more sensitive than cultivation in the detection of C. con-
cisus from gut mucosal biopsies, it is possible that some 
of the DNA detected could be remnants from the oral 
cavity in which C. concisus is abundant. Furthermore, 
cultivation of isolates is essential as it can contribute 
information regarding virulence properties and antibiotic 
susceptibility, providing useful knowledge when explor-
ing a possible association to different clinical illnesses. 
The cultivation of C. concisus from mucosal biopsies is 
tedious, but the prevalence of viable C. concisus is high in 
both IBD and healthy subjects, indicating that coloniza-
tion by C. concisus is not restricted to the oral cavity. It is 
plausible that C. concisus has capacities for conforming to 
different environmental settings through genetic and epi-
genetic variations, much like observed for C. jejuni [19]. 
Alterations in the genome during host infection could 
then explain the existence of C. concisus in different parts 
of the gastrointestinal tract, possibly also explaining the 
Table 2 Number of  C. concisus positive biopsies from  gut 
mucosal tissue, derived from  different incubation meth-
ods from IBD patients and healthy controls (HC) (p = 0.40)
Incubation method IBD (%) HC (%)
Microaerobic only 18 (25) 11 (39)
Anaerobic only 17 (24) 5 (18)
Both 36 (51) 12 (43)
Total 71 28
Table 3 The number of  C. concisus positive biopsies 
from  the total number of  biopsies obtained from  the dif-
ferent patient groups, by cultivation and PCR
Cultivation (%) PCR (%)
CD 9/61 (15) 21/61 (34)
UC 13/103 (13) 47/103 (46)
IPAA 30/81 (37) 53/81 (65)
HC 23/182 (13) 66/182 (36)
Total 75/427 (17.5) 187/427 (44)
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difference in nutritional requirements observed in the 
oral cavity, as opposed to the intestine.
Most Campylobacter species metabolize amino acids 
or tricarboxylic acid cycle intermediates for growth in 
microaerobic conditions. Six species, C. concisus, C. cur-
vus, C. gracilis, C. rectus, C. showae and C. ureolyticus 
have been described to require hydrogen or formate as 
an electron donor in this process [3]. Recently, Lee et al. 
examined the growth of C. concisus in different atmos-
pheres and observed that oral and enteric C. concisus iso-
lates grew in anaerobic conditions without the presence 
of H2, formate or fumarate, although the presence of H2 
increased growth [20].
Different methods for attaining microaerobic and 
anaerobic atmospheres for cultivation of Campylobacter 
species are available; most commonly the gas generat-
ing sachets or automated gas delivery systems. In previ-
ous studies, no significant difference in cultivation rates 
between the two systems has been observed, although 
it appears that colony size may increase when using the 
automated gas delivery system [21–23]. We found that 
combining initial anaerobic cultivation of mucosal tissue 
with traditional microaerobic cultivation yielded a high 
recovery rate for C. concisus. Invasive strains of C. con-
cisus have been shown to retain capacity for intracellu-
lar survival in host cells [24], possibly making growth in 
anaerobic atmospheres more favorable. It is remarkable 
that for IBD patients almost equal numbers of isolates 
grew in microaerobic and anaerobic environments, while 
the majority of isolates from healthy individuals grew in 
a microaerobic atmosphere only (Table  1), which could 
reflect a different pathogenic feature of IBD isolates. The 
prevalence of C. concisus in faecal samples from diarrheic 
patients has previously been found to be almost as high 
as for C. jejuni/C. coli [25]. In this study, we also found 
a high prevalence of C. concisus in faeces, although not 
as high as in gut mucosal biopsies. This may be because 
several biopsies were attained from each individual, and 
because incubation was performed in two different envi-
ronments. Stool and saliva samples were incubated in a 
microaerobic atmosphere only and as such, isolate yield 
may be inadequate and therefore underestimate the 
actual prevalence of viable C. concisus in these samples.
It cannot be ruled out, that the increased cultivation 
rate can be explained by simply cultivating on more than 
one agar plate, regardless of the incubation method used, 
and further studies to elucidate genetic differences in 
isolates recovered from the same site but different envi-
ronments, are currently undergoing in our laboratory. 
The percentage of subjects with at least one positive C. 
concisus biopsy was considerably larger in our study 
compared with previous findings, as was the isolate 
yield—probably due to the fact, that we examined more 
biopsies from each individual. While isolate yield was 
more extensive in IBD patients than healthy controls, 
there was no difference in the number of persons with at 
least one positive biopsy. This could indicate that gastro-
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Fig. 1 Percentage of C. concisus positive individuals in at least one biopsy, faeces and saliva by cultivation (cul) and PCR
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or abundance of C. concisus in the gastrointestinal tract, 
rather than only bacterial presence. We also found that 
UC patients with IPAA had a higher prevalence of C. con-
cisus in mucosal biopsies compared to other IBD patients 
and healthy controls. IPAA surgery is performed on 
UC patients with medically refractory disease or severe 
clinical complications. The higher prevalence of C. con-
cisus in IPAA patients could be associated to the history 
of severe inflammation, and the pathogenic potential of 
such isolates need to be evaluated. Previously, it has been 
proposed that the procedure for bowel preparations for 
colonoscopy could influence the isolation rates of C. con-
cisus, due to the induction of severe diarrhea that could 
flush the bacteria from the gut lumen [9]. Patients with 
IPAA do not undergo standard procedures for bowel 
preparations with induction of severe diarrhea, but diar-
rhea is a common clinical feature of their condition, so 
this is an unlikely explanation of the difference. By opti-
mizing cultivation procedures, this study has shown that 
C. concisus colonization in the gastrointestinal tract is 
extensive, warranting the need for further studies com-
paring isolates from IBD patients and healthy controls.
Conclusions
The rate of C. concisus detection by PCR was higher 
for IBD patients than healthy controls, similar to find-
ings in previous studies. The rate of C. concisus isolates 
recovered by cultivation was higher for IBD patients 
compared to healthy controls, but there was no differ-
ence in the proportion of individuals with at least one 
positive biopsy. Interestingly, the group of IBD patients 
with previous IPAA surgery had a higher rate of C. con-
cisus by both cultivation and PCR compared to other IBD 
patients. Combining traditional microaerobic incuba-
tion with a two-step procedure that incorporates initial 
anaerobic cultivation is laborious, but we found that this 
method facilitates a higher isolation rate of C. concisus 
than by microaerobic incubation exclusively.
Abbreviations
CD: Crohn’s disease; HC: healthy controls; IBD: inflammatory bowel disease; 
IPAA: ileal‑pouch‑anal‑anastomosis; PCR: polymerase chain reaction; qPCR: 
quantitative PCR (real‑time PCR); UC: ulcerative colitis.
Authors’ contributions
KFK was the main author on this paper, all other authors also assisted to the 
manuscript. OTU contributed with patient inclusion and biopsy collection. 
HN and HLN contributed with design of the study and advisory support. All 
authors accepted the final version of the manuscript. All authors read and 
approved the final manuscript.
Author details
1 Department of Infectious Diseases, Aalborg University Hospital, Aalborg, 
Denmark. 2 Department of Clinical Medicine, Aalborg University, Aalborg, 
Denmark. 3 Department of Clinical Microbiology, Aalborg University Hospital, 
Aalborg, Denmark. 4 Department of Gastrointestinal Surgery, Aalborg Univer‑
sity Hospital, Aalborg, Denmark. 
Acknowledgements
The authors would like to thank all the patients involved in the study, and 
Irene Harder Tarpgaard, MSc., Ph.D. for her help in the PCR laboratory. Part of 
this study was presented at the 18th International workshop on Campylobac-
ter, Helicobacter and Related Organisms (CHRO) 2015, Rotorua, New Zealand.
Availability of data and materials
Information regarding materials used in this study is provided in the manu‑
script. Human biological material has been stored in a research Biobank, in 
accordance with the Danish Health Authority regulations and with permission 
from the Ethics Committee of Northern Jutland, Denmark (N‑20130070).
Competing interests
The authors declare that they have no competing interests.
Funding
This work was supported by a Grant from Dr. Heinrich Kopps legate.
Received: 20 April 2016   Accepted: 19 May 2016
References
 1. Kaakoush NO, Castano‑Rodriguez N, Mitchell HM, Man SM. Global epide‑
miology of Campylobacter infection. Clin Microbiol Rev. 2015;28:687–720.
 2. Man SM. The clinical importance of emerging Campylobacter species. Nat 
Rev Gastroenterol Hepatol. 2011;8:669–85.
 3. Lastovica AJ, Allos BM. clinical significance of Campylobacter and related 
species, other than Campylobacter jejuni and Campylobacter coli. In: 
Nachamkin I, Szymanski CM, Blaser MJ, editors. Campylobacter. 3rd ed. 
Washington DC: ASM Press; 2008. p. 123–49.
 4. Vandamme P, Falsen E, Pot B, Hoste B, Kersters K, De Ley J. Identification of 
EF group 22 campylobacters from gastroenteritis cases as Campylobacter 
concisus. J Clin Microbiol. 1989;27:1775–81.
 5. Nielsen HL, Engberg J, Ejlertsen T, Bucker R, Nielsen H. Short‑term and 
medium‑term clinical outcomes of Campylobacter concisus infection. Clin 
Microbiol Infect. 2012;18:E459–65.
 6. Nielsen HL, Engberg J, Ejlertsen T, Nielsen H. Clinical manifestations 
of Campylobacter concisus infection in children. Pediatr Infect Dis J. 
2013;11:1194–8.
 7. Zhang L, Man SM, Day AS, Leach ST, Lemberg DA, Dutt S, Stormon M, 
Otley A, O’Loughlin EV, Magoffin A, Ng PH, Mitchell H. Detection and 
isolation of Campylobacter species other than C. jejuni from children with 
Crohn’s disease. J Clin Microbiol. 2009;47:453–5.
 8. Hansen R, Berry SH, Mukhopadhya I, Thomson JM, Saunders KA, Nicholl 
CE, Bisset WM, Loganathan S, Mahdi G, Kastner‑Cole D, Barclay AR, Bishop 
J, Flynn DM, McGrogan P, Russell RK, El‑Omar EM, Hold GL. The microaero‑
philic microbiota of de‑novo paediatric inflammatory bowel disease: the 
BISCUIT study. PLoS One. 2013;8:e58825.
 9. Mahendran V, Riordan SM, Grimm MC, Tran TA, Major J, Kaakoush NO, 
Mitchell H, Zhang L. Prevalence of Campylobacter species in adult Crohn’s 
disease and the preferential colonization sites of Campylobacter species 
in the human intestine. PLoS One. 2011;6:e25417.
 10. Mukhopadhya I, Thomson JM, Hansen R, Berry SH, El‑Omar EM, Hold 
GL. Detection of Campylobacter concisus and other Campylobacter 
species in colonic biopsies from adults with ulcerative colitis. PLoS One. 
2011;6:e21490.
 11. Castano‑Rodriguez N, Kaakoush NO, Lee WS, Mitchell HM. Dual role of 
Helicobacter and Campylobacter species in IBD: a systematic review and 
meta‑analysis. Gut. 2015. doi:10.1136/gutjnl‑2015‑310545.
 12. Kaakoush NO, Man SM, Lamb S, Raftery MJ, Wilkins MR, Kovach Z, Mitchell 
H. The secretome of Campylobacter concisus. FEBS J. 2010;277:1606–17.
 13. Deshpande NP, Kaakoush NO, Wilkins MR, Mitchell HM. Comparative 
genomics of Campylobacter concisus isolates reveals genetic diversity and 
provides insights into disease association. BMC Genomics. 2013;14:585.
 14. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory 
Bowel disease. Nature. 2011;474:307–17.
 15. Becker JM. Surgical therapy for ulcerative colitis and Crohn’s disease. 
Gastroenterol Clin North Am. 1999;28:371–90.
Page 6 of 6Kirk et al. Gut Pathog  (2016) 8:27 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 16. Nielsen HL, Engberg J, Ejlertsen T, Nielsen H. Comparison of polycarbon‑
ate and cellulose acetate membrane filters for isolation of Campylobacter 
concisus from stool samples. Diagn Microbiol Infect Dis. 2013;76:549–50.
 17. Nielsen HL, Mølvadgaard M, Nielsen H, Kostrzewa M. Identification and 
differentiation of highly diverse Campylobacter concisus strains using the 
MALDI biotyper. Clin microbial. 2016;5:230.
 18. Watt E, Farquarson F, El‑Omar EM, Louis P, Hold GL. Development of a 
q‑PCR strategy to detect Campylobacter concisus within biopsy samples 
[abstract]. Campylobacter, Helicobacter and related Organisms (CHRO) 
2013. 2013; P230.
 19. Jerome JP, Mansfield LS. Within‑host evolution of Campylobacter jejuni. 
In: Sheppard SK, editor. Campylobacter ecology and evolution. 1st ed. 
Norfolk: Caister Academic Press; 2014. p. 23–32.
 20. Lee H, Ma R, Grimm MC, Riordan SM, Lan R, Zhong L, Raftery M, Zhang L. 
Examination of the anaerobic growth of Campylobacter concisus strains. 
Int J Microbiol. 2014;2014:476047.
 21. Shahin M, Jamal W, Verghese T, Rotimi VO. Comparative evaluation of 
anoxomat and conventional anaerobic GasPak jar systems for the isola‑
tion of anaerobic bacteria. Med Princ Pract. 2003;12:81–6.
 22. Summanen PH, McTeague M, Vaisanen ML, Strong CA, Finegold SM. 
Comparison of recovery of anaerobic bacteria using the Anoxomat, 
anaerobic chamber, and GasPak jar systems. Anaerobe. 1999;5:5–9.
 23. Haines MD, Eberle KN, McDaniel CD, Kiess AS. Evaluating 3 gas‑delivery 
systems for culturing Campylobacter jejuni in a microaerophilic environ‑
ment. Poult Sci. 2011;90:2378–82.
 24. Burgos‑Portugal JA, Mitchell HM, Castano‑Rodriguez N, Kaakoush NO. 
The role of autophagy in the intracellular survival of Campylobacter 
concisus. FEBS Open Bio. 2014;4:301–9.
 25. Nielsen HL, Ejlertsen T, Engberg J, Nielsen H. High incidence of Campylo-
bacter concisus in gastroenteritis in North Jutland, Denmark: a popula‑
tion‑based study. Clin Microbiol Infect. 2013;19:445–50.
